<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/">
  <channel>
    <title>Invitro on Tenu Tech Brief</title>
    <link>https://cluster-site.onrender.com/tags/invitro/</link>
    <description>Recent content in Invitro on Tenu Tech Brief</description>
    <generator>Hugo -- 0.146.0</generator>
    <language>en-us</language>
    <lastBuildDate>Tue, 24 Feb 2026 06:03:48 +0000</lastBuildDate>
    <atom:link href="https://cluster-site.onrender.com/tags/invitro/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>Biotech Startup M&amp;A Is Reliably Delivering Some Big Exits</title>
      <link>https://cluster-site.onrender.com/posts/biotech-startup-ma-is-reliably-delivering-some-big-exits/</link>
      <pubDate>Wed, 18 Feb 2026 12:00:33 +0000</pubDate>
      <guid>https://cluster-site.onrender.com/posts/biotech-startup-ma-is-reliably-delivering-some-big-exits/</guid>
      <description>• Over past two years, biotech M&amp;amp;A exceeded $38B, surpassing many historic tech exits. • 2026 kickoff: Eli Lilly to pay up to $2.4B for Orna Therapeutics, boosting in‑vivo cell the</description>
    </item>
  </channel>
</rss>
